News Releases

Immunic, Inc. to Participate in Investor and Scientific Conferences in November

November 10, 2020November 10, 2020

Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 5, 2020November 5, 2020

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

November 2, 2020November 2, 2020

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

October 20, 2020October 20, 2020

Immunic, Inc. to Participate in Scientific Conferences in October

September 29, 2020September 29, 2020

← Previous 1 2 3 4 … 16 Next →

Media and Investor Inquiries

Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com